Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
<Bundle xmlns="http://hl7.org/fhir">
<id value="bundlepackageleaflet-en-029daacbd89e23b3c2659a90ebac249a"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"/>
</meta>
<language value="en"/>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="None"/>
</identifier>
<type value="document"/>
<timestamp value="2023-06-27T10:09:22Z"/>
<entry>
<fullUrl
value="Composition/composition-en-029daacbd89e23b3c2659a90ebac249a"/>
<resource>
<Composition>
<id value="composition-en-029daacbd89e23b3c2659a90ebac249a"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"/>
</meta>
<language value="en"/>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><a name="Composition_composition-en-029daacbd89e23b3c2659a90ebac249a"> </a><p class="res-header-id"><b>Generated Narrative: Composition composition-en-029daacbd89e23b3c2659a90ebac249a</b></p><a name="composition-en-029daacbd89e23b3c2659a90ebac249a"> </a><a name="hccomposition-en-029daacbd89e23b3c2659a90ebac249a"> </a><a name="composition-en-029daacbd89e23b3c2659a90ebac249a-en-US"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">Language: en</p><p style="margin-bottom: 0px">Profile: <a href="https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-Composition-uv-epi.html">Composition (ePI)</a></p></div><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/07/391/005</p><p><b>status</b>: Final</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi/ 100000155538}">Package Leaflet</span></p><p><b>category</b>: <span title="Codes:{http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs R}">Raw</span></p><p><b>date</b>: 2022-02-16 13:28:17+0000</p><p><b>author</b>: <a href="Organization-mah-ema.html">Organization ACME industry</a></p><p><b>title</b>: TEST PURPOSES ONLY - revlimid</p><h3>Attesters</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Mode</b></td><td><b>Time</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://hl7.org/fhir/composition-attestation-mode official}">Official</span></td><td>2022-02-16 13:28:17+0000</td></tr></table></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/07/391/005"/>
</identifier>
<status value="final"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package Leaflet"/>
</type>
<category>
<coding>
<system
value="http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs"/>
<code value="R"/>
<display value="Raw"/>
</coding>
</category>
<subject>
<reference
value="MedicinalProductDefinition/mp029daacbd89e23b3c2659a90ebac249a"/>
</subject>
<date value="2022-02-16T13:28:17Z"/>
<author>🔗
<reference value="Organization/mah-ema"/>
</author>
<title value="TEST PURPOSES ONLY - revlimid"/>
<attester>
<mode>
<coding>
<system
value="http://hl7.org/fhir/composition-attestation-mode"/>
<code value="official"/>
</coding>
</mode>
<time value="2022-02-16T13:28:17Z"/>
</attester>
<section>
<title value="B. Package Leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="B. Package Leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
<emptyReason>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/list-empty-reason"/>
<code value="unavailable"/>
</coding>
</emptyReason>
<section>
<title value="Package leaflet: Information for the user"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package leaflet: Information for the user"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"></div>
</text>
</section>
<section>
<title value="What is in this leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="What is in this leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What is in this leaflet</p><ol type="1"><li>What Revlimid is and what it is used for</li><li>What you need to know before you take Revlimid</li><li>How to take Revlimid</li><li>Possible side effects</li><li>How to store Revlimid</li><li>Contents of the pack and other information</li></ol></div>
</text>
</section>
<section>
<title value="1. What revlimid is and what it is used for"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="1. What revlimid is and what it is used for"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What Revlimid is Revlimid contains the active substance lenalidomide . This medicine belongs to a group of medicines which affect how your immune system works.</p><p>What Revlimid is used for Revlimid is used in adults for:</p><ul><li>Multiple myeloma</li><li>Myelodysplastic syndromes</li><li>Mantle cell lymphoma</li><li>Follicular lymphoma</li></ul><p>Multiple myeloma Multiple myeloma is a type of cancer which affects a certain kind of white blood cell, called the plasma cell. These cells collect in the bone marrow and divide, becoming out of control. This can damage the bones and kidneys.</p><p>Multiple myeloma generally cannot be cured. However, the signs and symptoms can be greatly reduced or disappear for a period of time. This is called a response .</p><p>Newly diagnosed multiple myeloma in patients who have had a bone marrow transplant Revlimid is used on its own as a maintenance therapy after patients have recovered enough following a bone marrow transplant.</p><p>Newly diagnosed multiple myeloma in patients who cannot have a bone marrow transplant Revlimid is taken with other medicines. These may include:</p><ul><li>a chemotherapy medicine called bortezomib</li><li>an anti-inflammatory medicine called dexamethasone</li><li>a chemotherapy medicine called melphalan and</li><li>an immunosuppressant medicine called prednisone .<br/>You will take these other medicines at the start of treatment and then continue to take Revlimid on its own.</li></ul><p>If you are aged 75 years or older or have moderate to severe kidney problems - your doctor will check you carefully before starting treatment.</p><p>Multiple myeloma in patients who have had treatment before Revlimid is taken together with an anti-inflammatory medicine called dexamethasone .</p><p>Revlimid can stop the signs and symptoms of multiple myeloma getting worse. It has also been shown to delay multiple myeloma from coming back following treatment.</p><p>Myelodysplastic syndromes (MDS) MDS are a collection of many different blood and bone marrow diseases. The blood cells become abnormal and do not function properly. Patients can experience a variety of signs and symptoms including a low red blood cell count (anaemia), the need for a blood transfusion, and be at risk of infection.</p><p>Revlimid is used alone to treat adult patients who have been diagnosed with MDS, when all of the following apply:</p><ul><li>you need regular blood transfusions to treat low levels of red blood cells ( transfusion-dependent anaemia )</li><li>you have an abnormality of cells in the bone marrow called an isolated deletion 5q cytogenetic abnormality . This means your body does not make enough healthy blood cells</li><li>other treatments have been used before, are not suitable or do not work well enough.</li></ul><p>Revlimid can increase the number of healthy red blood cells that the body produces by reducing the number of abnormal cells:</p><ul><li>this can reduce the number of blood transfusions needed. It is possible that no transfusions will be needed.</li></ul><p>Mantle cell lymphoma (MCL) MCL is a cancer of part of the immune system (the lymph tissue). It affects a type of white blood cell called B-lymphocytes or B-cells. MCL is a disease where B-cells grow in an uncontrolled way and build up in the lymph tissue, bone marrow or blood.</p><p>Revlimid is used alone to treat adult patients who have previously been treated with other medicines.</p><p>Follicular lymphoma (FL) FL is a slow growing cancer that affects the B-lymphocytes. These are a type of white blood cells that help your body fight infection. When you have FL, too many of these B-lymphocytes may collect in your blood, bone marrow, lymph nodes and spleen.</p><p>Revlimid is taken together with another medicine called rituximab for the treatment of adult patients with previously treated follicular lymphoma.</p><p>How Revlimid works Revlimid works by affecting the body s immune system and directly attacking the cancer. It works in a number of different ways:</p><ul><li>by stopping the cancer cells developing</li><li>by stopping blood vessels growing in the cancer</li><li>by stimulating part of the immune system to attack the cancer cells.</li></ul></div>
</text>
</section>
<section>
<title value="2. What you need to know before you take revlimid"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text
value="2. What you need to know before you take revlimid"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>You must read the package leaflet of all medicinal products to be taken in combination with Revlimid before starting treament with Revlimid.</p><p>Do not take Revlimid:</p><ul><li>if you are pregnant, think you may be pregnant or are planning to become pregnant, as Revlimid is expected to be harmful to an unborn child (see section 2, Pregnancy, breast-feeding and contraception information for women and men ).</li><li>if you are able to become pregnant, unless you follow all the necessary measures to prevent you from becoming pregnant (see section 2, Pregnancy, breast-feeding and contraception information for women and men ). If you are able to become pregnant, your doctor will record with each prescription that the necessary measures have been taken and provide you with this confirmation.</li><li>if you are allergic to lenalidomide or any of the other ingredients of this medicine listed in section 6. If you think you may be allergic, ask your doctor for advice.</li></ul><p>If any of these apply to you, do not take Revlimid. Talk to your doctor if you are not sure.</p><p>Warnings and precautions Talk to your doctor, pharmacist or nurse before taking Revlimid if:</p><ul><li>you have had blood clots in the past - you have an increased risk of developing blood clots in the veins and arteries during treatment</li><li>you have any signs of an infection, such as a cough or fever</li><li>you have or have ever had previous viral infection, particularly: hepatitis B infection, varicella zoster, HIV. If you are in doubt, talk to your doctor. Treatment with Revlimid may cause the virus to become active again, in patients who carry the virus. This results in a recurrence of the infection. Your doctor should check whether you have ever had hepatitis B infection</li><li>you have kidney problems - your doctor may adjust your dose of Revlimid</li><li>you have had a heart attack, have ever had a blood clot, or if you smoke, have high blood pressure or high cholesterol levels</li><li>you have had an allergic reaction whilst taking thalidomide (another medicine used to treat multiple myeloma) such as rash, itching, swelling, dizziness or trouble breathing</li><li>you have experienced in the past a combination of any of the following symptoms: widespread rash, red skin, high body temperature, flu-like symptoms, liver enzyme elevations, blood abnormalities (eosinophilia), enlarged lymph nodes these are signs of a severe skin reaction called Drug Reaction with Eosinophilia and Systemic Symptoms which is also known as DRESS or drug hypersensitivity syndrome. (see also section 4 Possible side effects ).</li></ul><p>If any of the above apply to you, tell your doctor, pharmacist or nurse before starting treatment.</p><p>At any time during or after your treatment, tell your doctor or nurse immediately if you:</p><ul><li><p>experience blurred, loss of or double vision, difficulty speaking, weakness in an arm or a leg, a change in the way you walk or problems with your balance, persistent numbness, decreased sensation or loss of sensation, memory loss or confusion. These may all be symptoms of a serious and potentially fatal brain condition known as progressive multifocal leukoencephalopathy (PML). If you had these symptoms prior to treatment with Revlimid, tell your doctor about any change in these symptoms.</p></li><li><p>experience shortness of breath, tiredness, dizziness, pain in the chest, a faster heartbeat, or swelling in the legs or ankles. These may be symptoms of a serious condition known as pulmonary hypertension (see section 4).</p></li></ul><p>Tests and checks Before and during the treatment with Revlimid you will have regular blood tests. This is because Revlimid may cause a fall in the blood cells that help fight infection (white blood cells) and help the blood to clot (platelets).<br/>Your doctor will ask you to have a blood test:</p><ul><li>before treatment</li><li>every week for the first 8 weeks of treatment</li><li>then at least every month after that.</li></ul><p>You may be evaluated for signs of cardiopulmonary problems before and during the treatment with lenalidomide.</p><p>For patients with MDS taking Revlimid If you have MDS, you may be more likely to get a more advanced condition called acute myeloid leukaemia (AML). In addition, it is not known how Revlimid affects the chances of you getting AML. Your doctor may therefore do tests to check for signs which may better predict the likelihood of you getting AML during your treatment with Revlimid.</p><p>For patients with MCL taking Revlimid Your doctor will ask you to have a blood test:</p><ul><li>before treatment</li><li>every week for the first 8 weeks (2 cycles) of treatment</li><li>then every 2 weeks in cycles 3 and 4 (see section 3 Treatment cycle for more information)</li><li>after this it will happen at the start of each cycle and</li><li>at least every month.</li></ul><p>For patients with FL taking Revlimid Your doctor will ask you to have a blood test:</p><ul><li>before treatment</li><li>every week for the first 3 weeks (1 cycle) of treatment</li><li>then every 2 weeks in cycles 2 to 4 (see Section 3 Treatment cycle for more information)</li><li>After this it will happen at the start of each cycle and</li><li>at least every month.</li></ul><p>Your doctor may check if you have a high total amount of tumour throughout the body, including your bone marrow. This could lead to a condition where the tumours break down and cause unusual levels of chemicals in the blood which can lead to kidney failure (this condition is called Tumour Lysis Syndrome ).</p><p>Your doctor may check you for changes to your skin such as red spots or rashes.</p><p>Your doctor may adjust your dose of Revlimid or stop your treatment based on the results of your blood tests and on your general condition. If you are newly diagnosed, your doctor may also assess your treatment based on your age and other conditions you already have.</p><p>Blood donation You should not donate blood during treatment and for at least 7 days after the end of treatment.</p><p>Children and adolescents Revlimid is not recommended for use in children and adolescents under 18 years.</p><p>Elderly and people with kidney problems If you are aged 75 years or older or have moderate to severe kidney problems - your doctor will check you carefully before starting treatment.</p><p>Other medicines and Revlimid Tell your doctor or nurse if you are taking or have recently taken any other medicines. This is because Revlimid can affect the way some other medicines work. Also, some other medicines can affect the way Revlimid works.</p><p>In particular, tell your doctor or nurse if you are taking any of the following medicines:</p><ul><li>some medicines used to prevent pregnancy such as oral contraceptives, as they may stop working</li><li>some medicines used for heart problems such as digoxin</li><li>some medicines used to thin the blood such as warfarin.</li></ul><p>Pregnancy, breast-feeding and contraception - information for women and men</p><p>Pregnancy<br/>For women taking Revlimid</p><ul><li>You must not take Revlimid if you are pregnant, as it is expected to be harmful to an unborn baby.</li><li>You must not become pregnant while taking Revlimid. Therefore you must use effective methods of contraception if you are a woman of childbearing potential (see Contraception ).</li><li>If you do become pregnant during your treatment with Revlimid, you must stop the treatment and inform your doctor immediately.</li></ul><p>For men taking Revlimid</p><ul><li>If your partner becomes pregnant whilst you are taking Revlimid, you should inform your doctor immediately. It is recommended that your partner seeks medical advice.</li><li>You must also use effective methods of contraception (see Contraception ).</li></ul><p>Breast-feeding You must not breast-feed when taking Revlimid, as it is not known if Revlimid passes into breast milk.</p><p>Contraception For women taking Revlimid Before starting the treatment, ask your doctor if you are able to become pregnant, even if you think this is unlikely.</p><p>If you are able to become pregnant</p><ul><li>you will have pregnancy tests under the supervision of your doctor (before every treatment, at least every 4 weeks during treatment, and at least 4 weeks after the treatment has finished) except where it has been confirmed that the fallopian tubes have been severed and sealed, to stop eggs from reaching the uterus (tubal sterilisation) AND</li><li>you must use effective methods of contraception for at least 4 weeks before starting treatment, during treatment, and until at least 4 weeks after stopping treatment. Your doctor will advise you on appropriate methods of contraception.</li></ul><p>For men taking Revlimid Revlimid passes into human semen. If your female partner is pregnant or able to become pregnant, and she does not use effective methods of contraception, you must use condoms during treatment and for at least 7 days after the end of treatment, even if you have had a vasectomy. You should not donate semen or sperm during treatment and for at least 7 days after the end of treatment.</p><p>Driving and using machines Do not drive or operate machines if you feel dizzy, tired, sleepy, have vertigo or blurred vision after taking Revlimid.</p><p>Revlimid contains lactose Revlimid contains lactose. If you have been told by your doctor that you have intolerance to some sugars, contact your doctor before taking this medicine.</p></div>
</text>
</section>
<section>
<title value="3. How to take revlimid"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="3. How to take revlimid"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Revlimid must be given to you by healthcare professionals with experience in treating multiple myeloma, MDS, MCL or FL.</p><ul><li>When Revlimid is used to treat multiple myeloma in patients who cannot have a bone marrow transplant or have had other treatments before, it is taken with other medicines (see section 1 What Revlimid is used for ).</li><li>When Revlimid is used to treat multiple myeloma in patients who have had a bone marrow transplant or to treat patients with MDS or MCL, it is taken alone.</li><li>When Revlimid is used to treat follicular lymphoma, it is taken with another medicine called rituximab .</li></ul><p>Always take Revlimid exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p>If you are taking Revlimid in combination with other medicines, you should refer to the package leaflets for these medicines for further information on their use and effects.</p><p>Treatment cycle Revlimid is taken on certain days over 3 weeks (21 days).</p><ul><li>Every 21 days is called a treatment cycle .</li><li>Depending on the day of the cycle, you will take one or more of the medicines. However, on some days you do not take any of the medicines.</li><li>After completing every 21-day cycle, you should start a new cycle over the next 21 days.<br/>OR Revlimid is taken on certain days over 4 weeks (28 days).</li><li>Every 28 days is called a treatment cycle .</li><li>Depending on the day of the cycle, you will take one or more of the medicines. However, on some days you do not take any of the medicines.</li><li>After completing every 28-day cycle, you should start a new cycle over the next 28 days.</li></ul><p>How much Revlimid to take Before you start treatment, your doctor will tell you:</p><ul><li>how much Revlimid you should take</li><li>how much of the other medicines you should take in combination with Revlimid, if any</li><li>on what days of your treatment cycle to take each medicine.</li></ul><p>How and when to take Revlimid</p><ul><li>swallow the capsules whole, preferably with water.</li><li>do not break, open or chew the capsules. If powder from a broken Revlimid capsule makes contact with the skin, wash the skin immediately and thoroughly with soap and water.</li><li>healthcare professionals, caregivers and family members should wear disposable gloves when handling the blister or capsule. Gloves should then be removed carefully to prevent skin exposure, placed in a sealable plastic polyethylene bag and disposed of in accordance with local requirements. Hands should then be washed thoroughly with soap and water. Women who are pregnant or suspect they may be pregnant should not handle the blister or capsule.</li><li>the capsules can be taken either with or without food.</li><li>you should take Revlimid at about the same time on the scheduled days.</li></ul><p>Taking this medicine To remove the capsule from the blister:</p><ul><li>press only one end of the capsule out to push it through the foil</li><li>do not put pressure on the centre of the capsule, as this can cause it to break.</li></ul><p>Duration of the treatment with Revlimid Revlimid is taken in treatment cycles, each cycle lasting 21 or 28 days (see above Treatment cycle ). You should continue the cycles of treatment until your doctor tells you to stop.</p><p>If you take more Revlimid than you should If you take more Revlimid than was prescribed, tell your doctor immediately.</p><p>If you forget to take Revlimid If you forget to take Revlimid at your regular time and:</p><ul><li>less than 12 hours have passed - take your capsule immediately.</li><li>more than 12 hours have passed - do not take your capsule. Take your next capsule at the usual time the next day.</li></ul><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p></div>
</text>
</section>
<section>
<title value="4. Possible side effects"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="4. Possible side effects"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Like all medicines, Revlimid can cause side effects, although not everybody gets them.</p><p>Stop taking Revlimid and see a doctor straight away if you notice any of the following serious side effects you may need urgent medical treatment:</p><ul><li>Hives, rashes, swelling of eyes, mouth or face, difficulty breathing, or itching, which may be symptoms of serious types of allergic reactions called angioedema and anaphylactic reaction.</li><li>A serious allergic reaction that may begin as a rash in one area but spread with extensive loss of skin over the whole body (Stevens-Johnson syndrome and/or toxic epidermal necrolysis).</li><li>Widespread rash, high body temperature, liver enzyme elevations, blood abnormalities (eosinophilia), enlarged lymph nodes and other body organs involvement (Drug Reaction with Eosinophilia and Systemic Symptoms which is also known as DRESS or drug hypersensitivity syndrome). See also section 2. Tell your doctor straight away if you notice any of the following serious side effects:</li><li>Fever, chills, sore throat, cough, mouth ulcers or any other symptoms of infection including within the bloodstream (sepsis)</li><li>Bleeding or bruising in the absence of injury</li><li>Chest pain or leg pain</li><li>Shortness of breath</li><li>Bone pain, muscle weakness, confusion or tiredness that might be due to high level of calcium in the blood.</li></ul><p>Revlimid may reduce the number of white blood cells that fight infection and also the blood cells which help the blood to clot (platelets) which may lead to bleeding disorders such as nosebleeds and bruising.<br/>Revlimid may also cause blood clots in the veins (thrombosis).</p><p>Other side effects It is important to note that a small number of patients may develop additional types of cancer, and it is possible that this risk may be increased with Revlimid treatment. Therefore your doctor should carefully evaluate the benefit and risk when you are prescribed Revlimid.</p><p>Very common side effects (may affect more than 1 in 10 people):</p><ul><li>A fall in the number of red blood cells which may cause anaemia leading to tiredness and weakness</li><li>Rashes, itching</li><li>Muscle cramps, muscle weakness, muscle pain, muscle aches, bone pain, joint pain, back pain, pain in the extremities</li><li>Generalised swelling including swelling of your arms and legs</li><li>Weakness, tiredness</li><li>Fever and flu like symptoms including fever, muscle ache, headache, earache, cough and chills</li><li>Numbness, tingling or burning sensation to the skin, pains in hands or feet, dizziness, tremor</li><li>Decreased appetite, change in the way things taste</li><li>Increase in pain, tumour size or redness around the tumour</li><li>Weight loss</li><li>Constipation, diarrhoea, nausea, vomiting, stomach pain, heartburn</li><li>Low levels of potassium or calcium and/or sodium in the blood</li><li>Thyroid functioning less than it should be</li><li>Leg pain (which could be a symptom of thrombosis), chest pain or shortness of breath (which may be a symptom of blood clots in the lungs, called pulmonary embolism)</li><li>Infections of all types, including infection of the sinuses that surround the nose, infection of the lung and the upper respiratory tract</li><li>Shortness of breath</li><li>Blurred vision</li><li>Clouding of your eye (cataract)</li><li>Kidney problems which include kidneys not working properly or not being able to maintain normal function</li><li>Abnormal liver test results</li><li>Increase in liver test results</li><li>Changes to a protein in the blood that can cause swelling of the arteries (vasculitis)</li><li>Increases in your blood sugar levels (diabetes)</li><li>Decreases in your blood sugar levels</li><li>Headache</li><li>Nosebleed</li><li>Dry skin</li><li>Depression, mood change, difficulty sleeping</li><li>Cough</li><li>A fall in blood pressure</li><li>A vague feeling of bodily discomfort, feeling bad</li><li>Sore inflamed mouth, dry mouth</li><li>Dehydration</li></ul><p>Common side effects (may affect up to 1 in 10 people):</p><ul><li><p>Destruction of red blood cells (haemolytic anaemia)</p></li><li><p>Certain types of skin tumour</p></li><li><p>Bleeding of the gums, stomach, or bowels</p></li><li><p>Increased blood pressure, slow, fast or irregular heart beat</p></li><li><p>Increase in the amount of a substance which results from normal and abnormal breakdown of red blood cells</p></li><li><p>Increase in a type of protein that indicates inflammation in body</p></li><li><p>Darkening of your skin, discoloration of your skin resulting from bleeding underneath, typically caused by bruising, swelling of skin filled with blood, bruise</p></li><li><p>Increase in uric acid in the blood</p></li><li><p>Skin eruptions, redness of skin, cracking, flaking or peeling skin, hives</p></li><li><p>Increased sweating, night sweats</p></li><li><p>Difficulty swallowing, sore throat, difficulty with voice quality or voice changes</p></li><li><p>Runny nose</p></li><li><p>Production of much more or much less urine than usual or the inability to control when to urinate</p></li><li><p>Passing blood in the urine</p></li><li><p>Shortness of breath especially when lying down (which may be a symptom of heart failure)</p></li><li><p>Difficulty getting an erection</p></li><li><p>Stroke, fainting, vertigo (problem with inner ear which leads to feeling that everything is spinning), temporary loss of consciousness</p></li><li><p>Chest pain spreading to the arms, neck, jaw, back or stomach, feeling sweaty and breathless, feeling sick or vomiting, which may be symptoms of a heart attack (myocardial infarction)</p></li><li><p>Muscle weakness, lack of energy</p></li><li><p>Neck pain, chest pain</p></li><li><p>Chills</p></li><li><p>Joint swelling</p></li><li><p>Bile flow from liver slowed or blocked</p></li><li><p>Low levels of phosphate or magnesium in the blood</p></li><li><p>Difficulty speaking</p></li><li><p>Liver injury</p></li><li><p>Impaired balance, difficulty moving</p></li><li><p>Deafness, ringing in the ears (tinnitus)</p></li><li><p>Nerve pain, unpleasant abnormal sensation especially to touch</p></li><li><p>An excess of iron in the body</p></li><li><p>Thirst</p></li><li><p>Confusion</p></li><li><p>Toothache</p></li><li><p>Fall which may result in injury</p></li></ul><p>Uncommon side effects (may affect up to 1 in 100 people):</p><ul><li>Bleeding within the skull</li><li>Circulatory problems</li><li>Loss of vision</li><li>Loss of sex drive (libido)</li><li>Passing large amounts of urine with bone pain and weakness, which may be symptoms of a kidney disorder (Fanconi syndrome)</li><li>Yellow pigmentation to the skin, mucus membrane or eyes (jaundice), pale coloured stools, dark coloured urine, skin itch, rash, pain or swelling of the stomach these may be symptoms of injury to the liver (hepatic failure)</li><li>Stomach pain, bloating, or diarrhoea, which may be symptoms of inflammation in the large intestine (called colitis or caecitis)</li><li>Damage to the cells of the kidney (called renal tubular necrosis)</li><li>Changes to the colour of your skin, sensitivity to sunlight</li><li>Tumour lysis syndrome - metabolic complications that can occur during treatment of cancer and sometimes even without treatment. These complications are caused by the break-down products of dying cancer cells and may include the following: changes to blood chemistry; high potassium, phosphorus, uric acid, and low calcium consequently leading to changes in kidney function, heart beat, seizures, and sometimes death.</li><li>Increase in blood pressure within blood vessels that supply the lungs (pulmonary hypertension).</li></ul><p>Not known side effects (frequency cannot be estimated from the available data):</p><ul><li>Sudden, or mild but worsening pain in the upper stomach and/or back, which remains for a few days, possibly accompanied by nausea, vomiting, fever and a rapid pulse these symptoms may be due to inflammation of the pancreas.</li><li>Wheezing, shortness of breath or a dry cough, which may be symptoms caused by inflammation of the tissue in the lungs.</li><li>Rare cases of muscle breakdown (muscle pain, weakness or swelling) which can lead to kidney problems (rhabdomyolysis) have been observed, some of them when Revlimid is administered with a statin (a type of cholesterol lowering medicines).</li><li>A condition affecting the skin caused by inflammation of small blood vessels, along with pain in the joints and fever (leukocytoclastic vasculitis).</li><li>Breakdown of the wall of the stomach or gut. This may lead to very serious infection. Tell your doctor if you have severe stomach pain, fever, nausea, vomiting, blood in your stool, or changes in bowel habits.</li><li>Viral infections, including herpes zoster (also known as shingles , a viral disease that causes a painful skin rash with blisters) and recurrence of hepatitis B infection (which can cause yellowing of the skin and eyes, dark brown-colored urine, right-sided stomach pain, fever and feeling nauseous or being sick).</li><li>Rejection of solid organ transplant (such as kidney, heart).</li></ul><p>Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in 30TAppendix V30T. By reporting side effects you can help provide more information on the safety of this medicine.</p></div>
</text>
</section>
<section>
<title value="5. How to store revlimid"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="5. How to store revlimid"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><ul><li>Keep this medicine out of the sight and reach of children.</li><li>Do not use this medicine after the expiry date, which is stated on the blister and on the carton after EXP . The expiry date refers to the last day of that month.</li><li>This product does not require any special storage conditions.</li><li>Do not use this medicine if you notice any damage or signs of tampering to the pack.</li><li>Do not throw away any medicines via wastewater or household waste. Please return unused medicines to your pharmacist. These measures will help protect the environment.</li></ul></div>
</text>
</section>
<section>
<title value="6. Contents of the pack and other information"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="6. Contents of the pack and other information"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What Revlimid contains</p><p>Revlimid 2.5 mg hard capsules:</p><ul><li>The active substance is lenalidomide. Each capsule contains 2.5 mg of lenalidomide.</li><li>The other ingredients are:</li></ul><ul><li>capsule contents: anhydrous lactose (see section 2), microcrystalline cellulose, croscarmellose sodium and magnesium stearate</li><li>capsule shell: gelatine, titanium dioxide (E171), indigo carmine (E132) and yellow iron oxide (E172)</li><li>printing ink: shellac, propylene glycol (E1520), potassium hydroxide and black iron oxide (E172).</li></ul><p>Revlimid 5 mg hard capsules:</p><ul><li>The active substance is lenalidomide. Each capsule contains 5 mg of lenalidomide.</li><li>The other ingredients are:</li></ul><ul><li><p>capsule contents: anhydrous lactose (see section 2), microcrystalline cellulose, croscarmellose sodium and magnesium stearate</p></li><li><p>capsule shell: gelatine and titanium dioxide (E171)</p></li><li><p>printing ink: shellac, propylene glycol (E1520), potassium hydroxide and black iron oxide (E172).</p></li></ul><p>Revlimid 7.5 mg hard capsules:</p><ul><li>The active substance is lenalidomide. Each capsule contains 7.5 mg of lenalidomide.</li><li>The other ingredients are:</li></ul><ul><li>capsule contents: anhydrous lactose (see section 2), microcrystalline cellulose, croscarmellose sodium and magnesium stearate</li><li>capsule shell: gelatine, titanium dioxide (E171) and yellow iron oxide (E172)</li><li>printing ink: shellac, propylene glycol (E1520), potassium hydroxide and black iron oxide (E172).</li></ul><p>Revlimid 10 mg hard capsules:</p><ul><li>The active substance is lenalidomide. Each capsule contains 10 mg of lenalidomide.</li><li>The other ingredients are:</li></ul><ul><li>capsule contents: anhydrous lactose (see section 2), microcrystalline cellulose, croscarmellose sodium and magnesium stearate</li><li>capsule shell: gelatine, titanium dioxide (E171), indigo carmine (E132) and yellow iron oxide (E172)</li><li>printing ink: shellac, propylene glycol (E1520), potassium hydroxide and black iron oxide (E172).</li></ul><p>Revlimid 15 mg hard capsules:</p><ul><li>The active substance is lenalidomide. Each capsule contains 15 mg of lenalidomide.</li><li>The other ingredients are:</li></ul><ul><li>capsule contents: anhydrous lactose (see section 2), microcrystalline cellulose, croscarmellose sodium and magnesium stearate</li><li>capsule shell: gelatine, titanium dioxide (E171) and indigo carmine (E132)</li><li>printing ink: shellac, propylene glycol (E1520), potassium hydroxide and black iron oxide (E172).</li></ul><p>Revlimid 20 mg hard capsules:</p><ul><li>The active substance is lenalidomide. Each capsule contains 20 mg of lenalidomide.</li><li>The other ingredients are:</li></ul><ul><li>capsule contents: anhydrous lactose (see section 2), microcrystalline cellulose, croscarmellose sodium and magnesium stearate</li><li>capsule shell: gelatine and titanium dioxide (E171), indigo carmine (E132) and yellow iron oxide (E172)</li><li>printing ink: shellac, propylene glycol (E1520), potassium hydroxide and black iron oxide (E172).</li></ul><p>Revlimid 25 mg hard capsules:</p><ul><li>The active substance is lenalidomide. Each capsule contains 25 mg of lenalidomide.</li><li>The other ingredients are:</li></ul><ul><li>capsule contents: anhydrous lactose (see section 2), microcrystalline cellulose, croscarmellose sodium and magnesium stearate</li><li>capsule shell: gelatine and titanium dioxide (E171)</li><li>printing ink: shellac, propylene glycol (E1520), potassium hydroxide and black iron oxide (E172).</li></ul><p>What Revlimid looks like and contents of the pack</p><p>Revlimid 2.5 mg hard capsules are blue-green/white, with REV 2.5 mg written on them. The capsules are provided in packs. Each pack contains one or three blisters, each blister with seven capsules. This gives a total of 7 or 21 capsules per pack.</p><p>Revlimid 5 mg hard capsules are white, with REV 5 mg written on them. The capsules are provided in packs. Each pack contains one or three blisters, each blister with seven capsules. This gives a total of 7 or 21 capsules per pack.</p><p>Revlimid 7.5 mg hard capsules are pale yellow/white, with REV 7.5 mg written on them. The capsules are provided in packs. Each pack contains one or three blisters, each blister with seven capsules. This gives a total of 7 or 21 capsules per pack.</p><p>Revlimid 10 mg hard capsules are blue-green/pale yellow, with REV 10 mg written on them. The capsules are provided in packs. Each pack contains one or three blisters, each blister with seven capsules. This gives a total of 7 or 21 capsules per pack.</p><p>Revlimid 15 mg hard capsules are pale blue/white, with REV 15 mg written on them. The capsules are provided in packs. Each pack contains one or three blisters, each blister with seven capsules. This gives a total of 7 or 21 capsules per pack.</p><p>Revlimid 20 mg hard capsules are blue-green/pale blue, with REV 20 mg written on them. The capsules are provided in packs. Each pack contains one or three blisters, each blister with seven capsules. This gives a total of 7 or 21 capsules per pack.</p><p>Revlimid 25 mg hard capsules are white, with REV 25 mg written on them. The capsules are provided in packs. Each pack contains one or three blisters, each blister with seven capsules. This gives a total of 7 or 21 capsules per pack.</p><p>Marketing Authorisation Holder Bristol-Myers Squibb Pharma EEIG Plaza Blanchardstown Corporate Park 2 Dublin 15, D15 TIreland</p><p>Manufacturer Celgene Distribution B.V. Orteliuslaan 13528 BD Utrecht<br/>Netherlands</p><p>This leaflet was last revised in</p><p>Other sources of information:</p><p>Detailed information on this medicine is available on the website of the European Medicines Agency:</p></div>
</text>
</section>
</section>
</Composition>
</resource>
</entry>
<entry>
<fullUrl
value="MedicinalProductDefinition/mp029daacbd89e23b3c2659a90ebac249a"/>
<resource>
<MedicinalProductDefinition>
<id value="mp029daacbd89e23b3c2659a90ebac249a"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"/>
</meta>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><a name="MedicinalProductDefinition_mp029daacbd89e23b3c2659a90ebac249a"> </a><p class="res-header-id"><b>Generated Narrative: MedicinalProductDefinition mp029daacbd89e23b3c2659a90ebac249a</b></p><a name="mp029daacbd89e23b3c2659a90ebac249a"> </a><a name="hcmp029daacbd89e23b3c2659a90ebac249a"> </a><a name="mp029daacbd89e23b3c2659a90ebac249a-en-US"> </a><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/07/391/005</p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-type MedicinalProduct}">Medicinal Product</span></p><p><b>domain</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-domain Human}">Human use</span></p><p><b>status</b>: <span title="Codes:{http://hl7.org/fhir/publication-status active}">active</span></p><p><b>legalStatusOfSupply</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi 100000072084}">Medicinal product subject to medical prescription</span></p><blockquote><p><b>name</b></p><p><b>productName</b>: Revlimid 2.5 mg hard capsules</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000001}">Full name</span></p><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000002}">Invented name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000003}">Scientific name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000004}">Strength part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000005}">Pharmaceutical dose form part</span></p></blockquote><h3>Usages</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Country</b></td><td><b>Jurisdiction</b></td><td><b>Language</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:ietf:bcp:47 en}">en</span></td></tr></table></blockquote></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/07/391/005"/>
</identifier>
<type>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-type"/>
<code value="MedicinalProduct"/>
<display value="Medicinal Product"/>
</coding>
</type>
<domain>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-domain"/>
<code value="Human"/>
<display value="Human use"/>
</coding>
</domain>
<status>
<coding>
<system value="http://hl7.org/fhir/publication-status"/>
<code value="active"/>
<display value="active"/>
</coding>
</status>
<legalStatusOfSupply>
<coding>
<system value="https://spor.ema.europa.eu/rmswi"/>
<code value="100000072084"/>
<display
value="Medicinal product subject to medical prescription"/>
</coding>
</legalStatusOfSupply>
<name>
<productName value="Revlimid 2.5 mg hard capsules"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000001"/>
<display value="Full name"/>
</coding>
</type>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000002"/>
<display value="Invented name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000003"/>
<display value="Scientific name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000004"/>
<display value="Strength part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000005"/>
<display value="Pharmaceutical dose form part"/>
</coding>
</type>
</part>
<usage>
<country>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</country>
<jurisdiction>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</jurisdiction>
<language>
<coding>
<system value="urn:ietf:bcp:47"/>
<code value="en"/>
<display value="en"/>
</coding>
</language>
</usage>
</name>
</MedicinalProductDefinition>
</resource>
</entry>
</Bundle>
IG © 2021+ Gravitate Health Project. Package hl7.eu.fhir.ghepi#0.1.0 based on FHIR 5.0.0. Generated 2024-10-14
Links: Table of Contents |
QA Report
The Gravitate Health project has received funding from the IMI 2 Joint Undertaking under grant agreement No 945334.
This joint undertaking receives support from the EU H2020 research and innovation programme and EFPIA.
